Interim report
Page 1
Ref: 11/SE/LC/2026-27 Date: November 05, 2026 To, National Stock Exchange of India Limited (“NSE”) Listing Department Exchange Plaza, C -1 Block G, Bandra Kurla Complex Bandra (East), Mumbai – 400051 To, BSE Limited (“BSE”) Listing Department Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 NSE Scrip Symbol: SMT BSE Scrip Code: 545001 ISIN: INE356Y01018 ISIN: INE356Y01018 Subject: Outcome of Board Meeting, pursuant to Regulation 30 read with Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015 (“Listing Regulations”). Dear Sir/Madam, Pursuant to Regulation 30 and Regulation 33 read with Schedule III and other applicable provisions of the Listing Regulations, we would like to inform you that, the Board of Directors of the Sahajanand Medical Technologies Limited (“Company”), at its meeting held today, i.e., November 05, 2026, have inter-alia considered, approved the following business: 1. The Unaudited Standalone and Consolidated Financial Results along with Limited Review Report for Quarter and Half -year ended September 30, 2026 are enclosed herewith. 2. Investment by Sahajanand Medical Technologies Ireland Limited, Wholly Owned Subsidiary of the Company in SNP Medical Corp., a US based corporation registered in Delaware. Details as required under Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, (“SEBI Circular”) are enclosed herewith as Annexure A 3. Appointment of M/s Amit Jaste & Associates , Company Secretaries (CP. No. 12234) as the Secretarial Auditor of the Company for the term of five consecutive financial years commencing from FY 2026-27 to FY 2030-31, subject to the approval of shareholders of the Company. Details as required under Listing Regulations read with SEBI Circular are enclosed herewith as Annexure B The meeting commenced at 3:00 PM (IST) and concluded at 4:43 PM (IST). The above intimation is also available on the website of the Company at www.smtpl.com and on the website of BSE Limited and National Stock Exchange of India Limited. Kindly take the same on records. Thanking you, For Sahajanand Medical Technologies Limited Bhargav Dhirajlal Kotadia Managing Director & Chief Executive Officer DIN: 06575042
Page 2
Deloitte Haskins & SellsLLP Chartered Accountants One International Center, Tower 3, 31st Floor, Senapati Bapat Marg Elphinstone Road (West) Mumbai - 400 013 Maharashtra, India Tel: +91 22 6185 6000 Fax: +91 22 6185 4101 INDEPENDENT AUDITOR’SREVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF Sahajanand Medical Technologies Limited 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Sahajanand Medical Technologies Limited (“theParent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “theGroup”), for the quarter and six months ended September 30, 2026 (“theStatement”)being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations”). 2. This Statement, which is the responsibility of the Parent’sManagement and approved by the Parent’sBoard of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian AccountingStandard 34 “InterimFinancial Reporting”(“IndAS 34”),prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Reviewof Interim Financial Information Performed by the Independent Auditor of the Entity”,issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent’spersonnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4. The Statement includes the results of the following entities listed in Annexure A. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, includingthe manner in which it is to be disclosed, or that it contains any materialmisstatement. 6. We did not review the interim financial results of 6 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect totalassets of Rs. 21,098.46 lakhs as at September 30, 2026 and total revenues of Rs. 8,564.62 lakhs and Rs. 14,838.02 lakhs for the quarter and six months ended September 30, 2026, total net profit/(loss) after tax of Rs. 683.32 lakhs and Rs. (346.24) lakhs for the quarter and six months ended September 30, 2026 and total comprehensive income/ (loss) of Rs. 683.32 lakhs and Rs. (346.24) lakhs for the quarter and six months ended September 30, 2026 respectively and net cash inflow of Rs. 28.35 lakhs for the six months ended September 30, 2026, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Regd. OrSta^Qne International Center, Tower 3, 31st floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai-400 013, Maharashtra, India. Deloitte HaskinMLSells LLP is registered with Limited Liability having LLP identification No: AAB-8737
Page 3
Deloitte Haskins & Sells LLP Place: Mumbai Date: November 05,2026 Statement, in so far as it retates to the amounts and discLosures included in respect of these subsidiaries is based sotety on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conctusion on the Statement is not modifled in resoect of these matters. For Detoitte Haskins & Setts LLP Chartered Accountants Firm Registration No. 1 17366\,11l'!V- 1 0001 B Terence Lewis Partner Membership No. '107502 26to7 5o2T2-\<€KO trq3
Page 4
Deloitte Haskins & SellsLLP Annexure A: Sr. No. Name of the Entities: Parent ,] Sahajanand Medical Technotogies Limited Subsidiaries 2 SMT Cardiovascutar Private Limited 3 Sahajanand MedicalTechnologles lreLand Limited 4 Vascutar lnnovation Compa nV Limited 5 SMT Germa ny Gmbh 6 Sahajanand MedicatTechnotogies lberia SL / SMT lmportadora E Distribuidora De Produtos HospitaLares Ltda. Sl"1T Switzertand AG 9 SMT Potonia sp. Z o.o. 10 SMT CIS LLC 11 SMT France SAS 12 SMT USA Ltd 13 SMT Austratia PTY Ltd (w.e.f. Aprlt 01 , 2026)
Page 5
')t e Sahljanxnd M€dicol Technologica Limited RBisrcnd ofli@ sahjinand Es c. v.krmrimidi. Ner Dibl'ori. vcd Roid. sunr :re5 00.r. cL'jinr. tndr clNr u]1ll9Gl200lPLc010t2t. Enr{it: tn\ 610^ 3ft1fl$ ? snr f. wcbs Umudltcd Consrid.rd Sr{.ftcnr or Piofit ond lrr ao. r[r qrrd.rrid5k mdirh rtrdcd 30 tul,lcmbcr,1016 Chan36 in inrqlo 6 oIfinnicd so.d., nek in.rnde aM \q*-in.phsrc$ Dcp@i.rion aid amniston c$cn* r.r rcrar.d 'o u iq pc'iod,lq, Orhrcom0Ehen.n! In.ono Ir.tu rhr. sirr nor hc Nlturln.d rub&qlc ty to ren. o. tos Re.@surcmom Caid(Los) on dclined b.ncur obtiSarion Icmrhrr f,rrr hc Blurln.drubrquc{tyiolrcnr or rN] Ex.haigo grin on tEndflior of neicial tur€mcnr offorci$ opedrions Tor.r or hor comlEhe irlr. l i.o c ru) Toirr CohDfthcDhr h.one (V+VD Orh.. codnEh.Ddrc lmon. l0r rhc N.iod lxitbuirbre rol Told conpreh.ir* li.orc ror lhc p.rtod rnribuilbtc to: Prld.up cqunt ,irE..Dnrl Ore v!lu. ol Rr I D.r lhrrc) Elnlit Dcr.hrE(roh o.ttEd tor qu rd.r .d !L no t .ndcd): Baic (R!.) l"
Page 6
Explanatory Notes to the Unrudited Consolidated Finencial Resutts: l. The Unaudited Consolidated Financial Resulh for the quarter and six monlh ended 30 September,2026 have been reviewed by the Audil Comlnittee and approved by the Board 0f Directors at ther( respective meelings held on 05 Nov€mber,2026 and a lirnited reviewoflhe same has been oarried out by the SlalLttory Auditors ofthe Company lhe requirements ofRegulation 33 oflhe SEBI (Lisling Obligations and Disclosure Requirements) R€gulations 2015, ("Listirg Requirements') as amended. ExplanatoryNotes (together ref€ned to as the "Unaudited Consolidaled Financial Resuks',). in lndia and in lerms ofRegulation 33 ofthe Securilies and Exchange Board oflndia (Listing Obligations and Disclosure R€quiremenls) Regulations, 20t5, as amended. Company's performance, allocales resources as a single segment "Cardiovascular Devices". Accordingly, no s€parate disclosure ofsegment has been made. lhe Parent Company at wwwsmel.com. llor and on bc[rllofth( I]oard ofl)ir.rtr)r\ Sahairf and Medical I echrn)logrcs l.imrled DIN : 06575042 Place Mumbai Date : 05 November 2026 KL'ar.-Ad,q-"&'di Amit Kumar Khandelia ChiefFinancial Officer Place : Mumbai Date : 05 November 2026 #\M
Page 7
Sahajanand Medical Technologies Limited Regislered Oflice: Sahajanand Eslate, Wakharialyadi, Near Dabholi, Ved Road, Sural 395 004, cujarat,lndia ClNi U33l l9GJ200lPLC040l2l, Email investors.g(icvance@smt.in, Websire: wwrv smrpl.corn Unaudited Consolidated Strtem€nr ofAssets snd Liabitities ss st 30 Septe ber 2026 ,\s rl.llr Srptcnrl)cr. 2026 ,\\,t -ll Uarrh.2l)26 ASSf,TS Non-Cu rrent A$el3 (a) Property, Plant and Equiprnent (b) Rightofuse Asseis (c) Capatal Work-in-Progress (d) Goodwill (€) Other Intangible Assets (t Intangible assets under development (g) Firancial Assels (i) lnvestments (ii) toans (iii) Other Financial Assets (h) Income Tax Assets (net) (i) Defened Tax Assets (neo C) Olher Non-Current assets Total Non-Current A$ets Curr€nt Assets (a) lnventories (b) Financial Assets (i) Investments (ii) Trade Receivables (iii) Cash and Cash Equivalenls (iv) Olher Bank Balances (v) Loans (vi) Olher Financial Assets (c) Other Current Assets Totsl Current Assets Total Assets EQUITY AND LIABILITIf,S Equity (a) EqLritysharecapilal (b) Other equity Equity lltdbutabl€ to owners ofthe compiny (c) Non-controlling interest Tohl Equity Lirbilltics Non-Curreni Lirbilities (a) Financial Liabilities (i) Bonowings (ii) Lease Liabilities (iii) Other Financial Liabililies (c) Defened Tax Liabilities (net) Total Noll.Crrrent Lirbilities Current Liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease Liabilities (iii) Trade Payables total oulstanding dues ofmicro and smatt enterprises tolal outstanding dues of creditors other than micro and small enterpris€s (i!) Other Financial Liabrlilres (b) Orh.r Currcnr Liabililies (d) Cullenl lax Liabilrties (ne1) 'l ot{l (lurrcnt l.inbilities I'or9!.Lruh{{ics ,dr0ql6 w Dxt r i,b,r,ric\ ,,ffi 24,153.05 2.998_25 1,458.88 4,937.07 1,144 27 75.98 2,998.44 369.10 1,383.78 98.84 5,t82.38 1.64',7 _64 3,644_79 751.91 4,950.38 1,842.01 t49.25 2,245 06 382 08 1,509 t0 80.84 5.005.14 2.301.41 47,O41.88 33,026.96 3.301.28 31,8I4.80 7,816 40 31632 82.77 2,25t.89 6.948.75 46,764.46 10,908.79 3,610.33 28.62.5_46 7.409_30 139.08 66.14 2,580.75 7.538 25 85,5s9.17 110.878.10 t..12,607.05 r.27.6.12.56 98t.ll 72.74',t.20 98t 3l 68.564.91 73,724.51 802 47 69,5{6.22 .r83l3 7{.510.911 6,580 93 l,80t.ll 1,618.75 1t9.24 249.88 70,229.{5 4,948 l6 2,249 73 1,006.97 99.26 230_64 10,391.93 23,588 98 1,203.98 669 90 9.624 66 2,136.40 206_40 4.662_23 8,534.76 22,004.33 1,398.68 l,3l l.l8 9,740.08 8,408.35 1,587.40 170.00 4.258.33 r7,6ll{.1.1 .18,8?lt_3s 58,076.07 57.{ll. ll 1..12.607.(ls 1,27.6.12.sa) b\ l<n V N-Pftur,rs|,9 l"
Page 8
5rn e Sahtjanalld Medical Technologies Limited Registeied Ofice Sanajuand Eslale, Wakhaiawadi, Neu Dabholi, Ved Road, Sunr 105 004, cujarat,lndia CIN UI I I l9GJ200l PLC040I2 I , Edail iDveslos srievance@sml ir, Websilc www snlpl cotr) Unludit.d Consolidat.d Slal.n.nl ofCash fiows tor the iix nron(h cndcd 30 S.prc bfi,2026 Iin rhc \ir ontI pcriod I orlhc sir nrotrlh toiorl A Crlh flovi frem Op.rrting Activili6 Depr€ciarion lid lnonhadon €xp.nse Finance cosrs InteEsl income Sh.rc based parnent qptrses U.r€rlised exchanse (s3ln)4o$ Profrt on sle ofprop.rty, planl .id equipn€it (ieo Crin on &lminatio! oflqs Impaimeri ofFiiancial A$ers (ier) Provision no longer required vrifie. back Op.r.tins crrh [oM b.for. mov.m.nt lnworhingcrpilll Movem.nls in wortlng.tpitrl AdjN efl Jot (hcre@) / decrcay n' operuh's dssets: lnvehtories (iet of proYhion) Trad€ Receivabl€s and oln r ossets Ad|tdnet,t lu (dlqeog n ope4titE lidbilities: TBd. Psrbles and other liabiliries C$h g.nersr.d fmm op.rltlng actlvltls Nel incohe trx paid Ner c.sh getr.rrl.d fron op.i.dng rcdvitis (A) B C.rh llors fmn inv.rtitrg sctivitie Payne for purch.se ofPrcpdrty, Plsnt & Equipmeni C6pit.l Wort-in-Progr.ss, inlangibles, and inraogible uider delelopfrenl Procads fron $1. ofpropeny. phnt and equipmd Md Copitsl Work-in-0.ogrcss Purchaes ofequlry iislrumenB deligEled st FVTOCI Loaos giv.n to third pany/€dployees (net) Brnk deDosirs withdBwi/ (phced) (ner) {livestmeir)R€d.hprion in debt scurities (net) N.t..rh u.ed in invecting rctivitis (A) C C.!h lto$ fron fitran.in8 r.riviri.! Proc€eds froh lona-tm borowings Repaynent of long-tdn boroBinS, Pro@eds noi snonre.m borowio$ (net) Prymenr of leae liabilitid (priicipal) Paymenl of leaseliabilities (interest) Acquisilion ofnon{ontrolling interssl in a subsidiaryr N.l cxrh B.d ln nn..cingr.tiviri.r (C) N.t d.fi.8m in cali ,nd cash .quivdentr (A+E+C) Cash and ash .quivalenb .l l h. begi..ih8 o a r he period Les: Urrealised €xcnaose 8!it'/ (lo$) on .!sh ond cash equiyahir Cash ,nd ..!h .quivrlcrB .r th..nd oflh. !.riod Rocotrcilirlio! of c$h .nd c$h equivslents closlnq br.neof o$and o5h eqoivalent Csth lnd.a!h.qulvrl.nk cr ihe.rd otrh. !.rtod lPaynent nade on deleri.d basis lor acquisilio, of NCt in previous pedod 6,435.39 4,132.t8 1,335.81 o69.60) ,21.29 (t,442.17) (11.5, {6.83) (197.r3) 3,992,44 1.33945 I,t?8.62 ( t76 ?31 21121 242 al (29 6r) (25 6l) t34 t2 i8lsi \2.144.24) (2,431 04) 927 11 326 55 (2,759.00) (3,294.96) (4.213.28) 62.4t (159.67) (4.23) 316.90 lt6.l0 (5,670 23) 762 a3 (708 89) (80 t?) l2o4 44) 1,756 23 (r 25 06) (661 5?) (9s6r) (r,703 t?) 2l8rl (r,lll74) (62175) ( l20 66) (r.597 97) .110.95 (1.85)
Page 9
Deloitte Haskins & Sells LLP 1. Chartered Acaountants One lnternationa Center, Tower 3, 31sl F oor, SenapatiBapat Marg Elphinstone Road (West) Mumbal-400 013 lVaharashtra,lndia Tel:+91 22 6185 6000 Faxr+91 22 61854101 (Membership No.'1 07502) uDrN: 241 O 15o2- P X \, tr HI & orL INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF Sahajanand Medicat Technotogies Limited We have reviewed the accompanying Statement of Standatone Unaud ted Financiat Results of Sahajanand Medical, Technol.ogies Limited ("the Company"), for the quarrer and slx months ended September 30, 2026 (,,rhe Statement,,), being submitted by the Company pursuant to the requirement of Regutation 33 of the SEBI (Listing Obtigations and Disctosure Requirements) Regutations, 2015, as amended ("the Listlng Regutations"). This Statement, which is the responsibltity of the Company's Management and approved by the Company,s Board of Directors, has been prepared in accordance with the recognition and measurement pr ncipLes taid down in the lndian Accounting Standard 34 "lnterim Financiat Reporting" ("lnd AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules ssued thereunder and other accounting principtes generalty accepted ]n lndla and in compliance with Regutation 33 of the Listng Regulations. Our responsibility is to express a concLusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of lnterim Financial lnformation Pefformed by the lndependent Auditor of the Entity', issued by the lnstitute of Chartered Accountants of lndia (lCAl). A review of interlm financiaL information consists of making inquiries, primarily of the Company's personnel responsible for financiat and accounting matters, and apptying anatyticat and other rev ew procedures. A review is substantiatty tess in scope than an audit conducted in accordance with Standards on Auditing speclfied under section 143(1 0) of the Companies Act, 20'1 3 ancl conseq uently does not enabte us to obtain assurance that we woutd become aware of att sign ficant matters that might be identified in an audit. Accordingty, we do not express an audit opinion. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to betieve that the accompanying Statement, prepared in accordance with the recognition and measurement principles lald down in the aforesaid lndian Accounting Standard and other accounting principtes generatty accepted in lndia, has not disctosed the information required to be disctosed in terms of Regutation 33 of the SEBI (L sting Obtigations and Dlsctosure Requirements) Regulations, 20 15, as amended, inctuding the manner in which it is to be disctosed, or that it contains anv materiaI misstatement_ For DeLoitte Haskins & SeLts LLP Chartered Accountants (Firm's Registration No. 1 17366w,4r'r'-1000 18) Placer I.4umbai Date: November 05. 2026 Regd. OfficerOne lnternationa Center,Tower3,3lstfloor,SenapatiBapatMarg,ElphinstoneRoad(West),Mumbai,4000T3,Maharashtra,tndia. De oitte Haskins & Sells LLP is registered with L mited Liab ityhavingLLP dentif catlon No:MB-8737 (Partner) Terence Lewis
Page 10
E EE53 st lii 'Eat ll o- E ft- E,=-gE 2EgL(_;EE lS==CE miEi Es--r o.l E !3'=fiP (, i; s;Eqo:: g a \ .1 r'l r qq .t ..1 ..1 n qq e +,: a P d Es B? E Ztt* 5 E 5,E'E U E ^a : etEE: :- <aYc Ean E E E ET,S E 9; E P !E E3 cE E i IE E *i E gcE i;tE''iE FsE!0aoF sroEUtriioor: zi ^.! aE g I EEa r 5 eA a a I ! 9v a - t4: Ei E 4 EE:4E E 5gi!F s
Page 11
f,xplanalory Notes to the Interim Standalone Finsncirl Resultsl Financial Results"). 2015, as amended. webrire oflhe Compan) at l,R sn pl.com. Irorind on hchalfofihc ln)ard ofl)irc(tors Sahrlarard Nl!dr.rl I u.hnolr!rcs Lr.rrc(l DIN:06575042 tKLN.atL" fu,,[ Amil Kunrar KhaDdelia Chiet Inmncial Ofiicer Date: 05 November 2026Daic 05 Nolerrrber 1026 Manag|rg Dned f.P'qE/ \r- M
Page 12
Sahajanand Medical Technologies Limited Regislered Offrce Sahajanand Estalc, Wakhariawadi. Near Dabholi, Ved Road, Sural 395 004, Gujaral, India CIN:U331I9CJ200lPLC040I2I,Email invcstors gflevitnce@sml.in, Wcbsitc lww.smld.con Unaodited Strndalone Statement ofAssets rnd Liabilities rs el30 September, 2026 ls rt.]0 Scplr Dcr,2026 l\ nt J1 )lxrch. 2026 ASSf,TS Non-Current A$ets (a) Property, Plafl and Equipments (b) Right ofUse Assets (c) CapilalWork-in-Progress (d) coodwill (e) Other Inrangible Assets (0 Intangible assets under development (g) FinancialAssets (i) Inveshents (ii) Loans (iii) Other Financial Assets (h) Defened Tax Assers (nel) (i) Other Non'Cunent assels Totrl No&Current Asset! CrrrentAssets (a) Invenrories (b) FinancialAssels (i) Trade Receivables (ii) Cash and Cash Equivalenrs (iii) Other Bank Balances (iv) Loans (v) OlherFinancialAssets (c) Other Cunent Assets Tot l Current A$et! Totrl Assels EQUITY AND LIABILITIf,S f,quity (a) Equity share capital (b) Other equity Totrl Equiay Liabilities Non-Crrrent Lisbilities Financial Liabililies (i) Bonowings (ii) t ease Liabiliries (iii) Olh€r Financial Liabilities Tot8l Non-Current Lisbilitiee Current Lirbilities (a) FinancialLiabilities (i) Borrowings (ii) Lease Liabililies (iii) Trade Payables lotal oulstanding dues ofmicro and small enterprises lotal ouhtanding dues ofcreditoB other than micro and small enrerprises (iv) Other Financial Liabililies (b) Other Currenl Liabilities (c) Provisions (d) Currenl Tax Liabiliries (nel) Totrl Current Liabilities Total Liabitities Totol Equily lnd Lisbiliti€s 5,088 34 899 18 626 98 2,963 54 224 29 7598 54,24612 5,37154 881.14 2,43 t.8l 1.320.96 4,857.85 157.17 2.963.54 t52.41 149_25 50,151.39 5,373_99 921.49 2,312_63 1.369.03 70,130.08 14,066.84 I2,478.81 428_26 4_12 79.31 2,890.8t 69,631.00 15.063.88 I 1,651 6l 642 33 499 61 0l 8,82',t.39 J{.99u.6u .!{).-171.I5 1.05.128.76 t.09.001.15 98I,3I 68.837.89 981 ll 66.752 71 3,369 I8 310.61 643_37 69,819.20 67,71.1.02 2,595 38 445 0l 259 87 4,323.t6 l7,i 88 80 45312 609 44 4,t62.89 4,0s7 92 474_42 204.18 3,835.03 3,300.26 17,455.97 633_14 1,238.5 7 5,986.85 8,s22.45 408.77 168.83 10.9IJ6.{0 _]5,100.56 .1t.270.t3 r,05.12IJ.76 t.09,001.rs uL-l $^d
Page 13
fps Sahajanand Medical T€chnologies Limiaed Resislered Ofi.e Sahajanand EstaG, Wakhdiavadi, Near Dabholl, Ved Road, Surar -3es 00,1, Cuja,a(,lndra CIN Ul3ll9GJ200lPLC040l2l,Email inyBroB.grievance@snr in, Website: \msmlplcon Uncudited Slrndrlo.e Sliieoent otClsh no*s lor rhe sir ntonlh pcriod lnded 30 Scnlenber,2026 lor tl'r ri\ nurlh po nrd cnd(l 30 Scflctr,l,er. 2026 lin lhr si\ trx,rlh Dornd rtr,lcd l0 ScDt.Nhor. l0l5 A Crlh llo*s fron Op.r irAA.tivi(ia Prcfir(lo$) b.foft lu Depreoialion and amonisation expens€ Fi.af,ce cosrs lnt€resi income Shsre bsed paymenl expenses Unrcalisd exchase los (Profiryhs on r.l€ ol p@peiy, plant and equipment (ieo Gain on temin.lion ol lease Provkion for Impaimenl ofFinancial Ass€rs (n.0 Op.rilirg c8h flows b.aore mov.n.nl itr working .apihl Mov.m..& in Porkine crpit.l A.litstwnt kr deccrudle ihopeo hFaset': Inv..r6i!.s T6de Receivables and Other 6sels Adjt$twkt kr decrease in opetuting tidbilltles: Trade Payables 6nd olher liabihies C.5h gen.r.r.d fton/ (u6ed itr) opentitrg activiti.s Net income tax p.id N.t Cash g.n.r.r.d trom/(u!ed in) operdirs r.rivili$ (A) B Ctuh llo* froh itrv€rling lcrivilis Paymenr for purchde ofProperty, Pla.t & Equipnent, CapihlWo*-in-Pogre$, inrangibles, aid inrangibl. uider develophent Proceeds ftom sale ol prcpeny, plant and equipment and Capilal work-in-Prc$e$ Loans givei to subsidiary Loans repaid by subsidiary hterest eceiwd on Lolns given to subsidisries Loms siven lo Ehployes {nd) B.nk deposils placed (net) N.t Crsh g.n.rit.d frod(u!ed in) inv€rt i.g ..t ivitie6 (B) C Cash no{s from financins &livitiet Prcce.ds lrom non-currcnt bomwinss R.paymenls of non-curenr bonowinss Prc@eds ofshodr€m borcwinss (neo Paymenr oalede liabiliti€s (P .cipal) Payh.nl of lede liabilities (lnbesr) Profesional fe6 for l.chdcal and commercial dil,sence Nel c$h s.tr.r .d fronv (ured in) firrncins r.tiviti.s (C) N.t (d€cr.tu.yincrcN€ ir.!3h lnd c..t equivrl.nt (A+B+C) Cath a.d cdh equiv6le.b ar rhe besinnirs ofthc period C.ih rnd.!ch equivrl.nG th..nd olthe period Recorciliario! of .$h and c!6h €quivdenit Closing balrnce ol @h and c8h €quivalenB Crsh rnd c$h .qrivrlentc the.nd otrheperiod 2,606,7a 981.35 33395 {1e912) 224 56 6r9 57) 12 93) 969 t0 ('t4 32) 12.71 183 07 (1 04) (25 6l) 3,478.t8 (6,180 57) (61 00) (2,598.16) (3,09916) (2.1t.1.13) 1,.t52,25 (1,347 84) 30 l3 (4,764.95) 4,755.00 t92 26 (5.88) 2t.89 (r,040 07) 791.12 {3.378 7' r5000 (47.611 (r 6r) 6820 (t,It.rJ) 7?1.80 (261 t1) (307.22) (46 6l) t706.39) (r8 29) 3,41256 t2794tl 112 -76\ 2.166.)1 (21.1.07) (.r..rJr r.r) .121J.26 \ $^d l"
Page 14
Annexure-A Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, is as under: Sr. No. Particulars Details 1 Name of the target entity, details in brief such as size, turnover etc.; SNP Medical Corp. (“SNP”) Turnover of 2025: USD 3,00,000 2 Whether the acquisition would fall within related party transaction(s) Whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”; Yes. Yes, Ms. Priyanka Cohen (Promotor & Non-Executive Director of the Company) is a Director in SNP. The transaction is at Arm’s length basis. 3 Industry to which the entity being acquired belongs; Medical Device 4 Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity); Diversification of product portfolio within the existing main line of the business of the Company 5 Brief details of any governmental or regulatory approvals required for the acquisition; Not Applicable 6 Indicative time period for completion of the acquisition; Tentatively the acquisition would be completed by 31st March, 2027 7 Consideration - whether cash consideration or share swap or any other form and details of the same Cash Consideration 8 Cost of acquisition and/or the price at which the shares are acquired; Acquisition cost is upto USD 7,80,000/- (Price per share will be determined based on valuation of SNP) 9 Percentage of shareholding / control acquired and / or number of shares acquired; SMT Ireland holds 14.15% stake in SNP Medical Corporation as on 30 th September 2026 and with this new acquisition, the percentage would increase upto 17.19%. 10 Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief); SNP medical is a medical device startup based in the US and working on developing Medical Device. It is a US based corporation registered in Delaware on May 31, 2022. Revenue details are as below for last three calendar years 2025: USD 3,00,000 2024: USD 2,34,960 2023: USD 5,64,930
Page 15
Annexure-B Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, is as under: Sr. No. Particulars Details 1 Reason for Change Appointment of M/s. Amit Jaste & Associates, Company Secretaries (CP. No. 12234) as the Secretarial Auditor of the Company. 2 Date of Appointment /cessation and term of Appointment Appointment as Secretarial Auditors w.e.f. 05 November 2026 for the financial year 2026-27 to 2030-31, subject to the approval of Shareholders of the Company. 3 Brief Profile (in case of Appointment) M/s. Amit Jaste & Associates is a firm of Practising Company Secretaries with offices in Mumbai and Pune. It is led by its Founder, Mr. Amit Jaste, a Fellow Member of the Institute of Company Secretaries of India and a Law Graduate. He has over 22 years of experience, including about a decade heading the corporate legal and secretarial function of a Company. The firm provides secretarial audit, corporate compliance, legal advisory and transaction advisory services. Its areas of practice include mergers and acquisitions, insolvency and bankruptcy matters, adjudication and compounding, and representation before the National Company Law Tribunal. The firm also advises corporates on governance frameworks and business structuring. Its clients include reputed listed and unlisted Companies and multinational corporations across sectors. The firm holds a valid Peer Review Certificate No. 1751/2022 issued by the ICSI. 4 Disclosure of relationships between Directors (in case of Appointment of a director) Not Applicable